Gonadotrophin releasing hormone analogues for the management of placenta accreta: A novel concept

Appiah-Sakyi, Kwabena; Fatima, Zebi; Anjum, Z.K.

doi:10.1080/01443610701467309

Search citation statements

Order By: Relevance

Paper Sections

Select...

Management1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent interventions include expectant management (65), uterine artery embolization (UAE) followed by expectant management (66), and adjuvant medical treatment. The latter includes adjuvant MTX treatment (67,68), novel adjuvant treatment by gonadotropin releasing hormone analogues (69), and mifepristone and misoprostol (70).…”

Section: Managementmentioning

confidence: 99%

Abnormal Placental Invasion—a Novel Approach to Treatment

Ophir¹,

Singer-Jordan²,

Odeh³

et al. 2009

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

The incidence of abnormal placental invasion has increased 10-fold in the past 50 years, reflecting the increased number of cesarean sections performed. Management relies on accurate early diagnosis with appropriate perioperative multidisciplinary planning to anticipate and avoid massive obstetric hemorrhage at delivery. Women at risk should plan to deliver at an institution with appropriate expertise and resources for managing this condition. We report a case of placenta increta management comprising preoperative placement of a pelvic artery balloon catheter, prophylactic balloon occlusion after delivery of the fetus, and embolization-assisted resection of the invaded uterine wall. We review incidence, methods of prenatal diagnosis, risk factors, and management of abnormally invasive placenta.

show abstract